drugset / Trial / NCT07476066
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
Phase 1/2
Not yet recruiting
374 enrolled
Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II clinical study conducted in participants with relapsed/refractory aggressive B-cell lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6055 Injection in participants with relapsed/refractory aggressive B-cell lymphoma, and to provide a basis for the recommended dosing regimen in subsequent studies.
Timeline
- Start
- 2026-03-15
- Primary completion
- 2029-03-15
- Completion
- 2031-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYS6055 | Unknown | — | — |